Home » Stocks » Larimar Therapeutics

Larimar Therapeutics, Inc. (LRMR)

Stock Price: $11.49 USD 0.99 (9.43%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed
After-hours: $11.00 -0.49 (-4.27%) Aug 11, 4:16 PM

Stock Price Chart

Key Info

Market Cap 176.44M
Revenue (ttm) n/a
Net Income (ttm) -35.89M
Shares Out 15.36M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $11.49
Previous Close $10.50
Change ($) 0.99
Change (%) 9.43%
Day's Open 10.51
Day's Range 9.01 - 11.49
Day's Volume 20,562
52-Week Range 7.43 - 20.28

More Stats

Market Cap 176.44M
Enterprise Value 131.99M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 15.36M
Float n/a
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share -10.98
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 53,606
Short Ratio 2.87
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.48
Revenue n/a
Operating Income -35.94M
Net Income -35.89M
Free Cash Flow -34.27M
Net Cash 44.45M
Net Cash / Share 2.89
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -280.42%
ROE -2,083.96%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$9.36*
Low
9.36
Current: $11.49
High
9.36
Target: 9.36
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue---------
Operating Income-45.65-61.12-53.00-58.23-73.81-35.53-13.78-13.79-13.15
Net Income-45.41-61.37-52.03-57.88-74.29-36.48-14.03-13.88-13.16
Shares Outstanding3.112.692.292.272.231.020.060.060.06
Earnings Per Share-14.64-22.80-22.80-25.44-33.36-36.00-234.36-235.80-230.04
Operating Cash Flow-40.78-51.49-43.78-51.98-59.55-28.24-15.00-13.59-12.27
Capital Expenditures-1.35-0.11-0.06-0.66-0.60-0.06-0.02--0.03
Free Cash Flow-42.13-51.60-43.84-52.64-60.15-28.30-15.02-13.59-12.31
Cash & Equivalents71.6011810212918511535.529.940.00
Total Debt22.5820.6420.003.596.397.56---
Net Cash / Debt49.0297.4382.0512617910835.529.940.00
Assets80.7312210613218911838.1410.99-
Liabilities27.1128.4927.299.8920.0013.082.922.93-
Book Value53.6293.2778.22122169104-68.57-54.73-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Larimar Therapeutics, Inc.
Country United States
Employees 16
CEO Carole S. Ben-Maimon

Stock Information

Ticker Symbol LRMR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: LRMR

Description

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead compound is CTI-1601, a Phase 1 clinical program to treat Friedreich's ataxia, a rare and progressive genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania.